CTAG2 and neoplasm: However, TCR- and antibody-based candidates employing a similar mechanism, such as bi-specific TCR-anti-CD3 constructs targeting NY-ESO-1/LAGE-1, have already proven their in vivo efficacy and tumor growth control using engineered TCRs directed against the same peptide.65